Drug nanocrystals in the commercial pharmaceutical development process.
about
Drug nanocrystals: A way toward scale-upNanomilling of Drugs for Bioavailability Enhancement: A Holistic Formulation-Process Perspective.Transformation of eutectic emulsion to nanosuspension fabricating with solvent evaporation and ultrasonication technique.Confined crystallization of fenofibrate in nanoporous silica.Characterization, Molecular Docking, and In Vitro Dissolution Studies of Solid Dispersions of 20(S)-Protopanaxadiol.High drug-loading nanomedicines: progress, current status, and prospects.Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.Elucidating the in vivo fate of nanocrystals using a physiologically based pharmacokinetic model: a case study with the anticancer agent SNX-2112.Conjugation of Hot-Melt Extrusion with High-Pressure Homogenization: a Novel Method of Continuously Preparing Nanocrystal Solid Dispersions.Production of nanoparticle drug delivery systems with microfluidics tools.Amorphous solid dispersion technique for improved drug delivery: basics to clinical applications.Combinative Particle Size Reduction Technologies for the Production of Drug Nanocrystals.A top-down technique to improve the solubility and bioavailability of aceclofenac: in vitro and in vivo studies.Nanocrystal for ocular drug delivery: hope or hype.Effects of PEGylated paclitaxel nanocrystals on breast cancer and its lung metastasis.Modeling the Time Course of the Tissue Responses to Intramuscular Long-acting Paliperidone Palmitate Nano-/Microcrystals and Polystyrene Microspheres in the Rat.Design and evaluation of injectable niclosamide nanocrystals prepared by wet media milling technique.Hyperoside nanocrystals for HBV treatment: process optimization, in vitro and in vivo evaluation.Formulation and delivery strategies of ibuprofen: Challenges and opportunities.Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.Chitosan based atorvastatin nanocrystals: effect of cationic charge on particle size, formulation stability, and in-vivo efficacy.Evaluation of systemic exposure of nanoparticle suspensions subcutaneously administered to mice regarding stabilization, volume, location, concentration and size.Drug nanocrystals for cancer therapy.Production of drug nanosuspensions: effect of drug physical properties on nanosizing efficiency.Design and in vitro characterization of ivermectin nanocrystals liquid formulation based on a top-down approach.Solubility and dissolution enhancement strategies: current understanding and recent trends.In Vitro and In Vivo Characterization of Drug Nanoparticles Prepared Using PureNano™ Continuous Crystallizer to Improve the Bioavailability of Poorly Water Soluble Drugs.Enhanced oral bioavailability of glycyrrhetinic acid via nanocrystal formulation.Nanoformulation of Leonotis leonurus to improve its bioavailability as a potential antidiabetic drug.Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.The Effect of an Optimized Wet Milling Technology on the Crystallinity, Morphology and Dissolution Properties of Micro- and Nanonized Meloxicam.Development of ternary solid dispersions with hydrophilic polymer and surface adsorbent for improving dissolution rate of carbamazepine.Recent advances in improving oral drug bioavailability by cocrystalsNanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical StabilityLambda-Cyhalothrin Nanosuspension Prepared by the Melt Emulsification-High Pressure Homogenization Method
P2860
Q26744024-CD580150-CB07-413A-8026-61463FDFB073Q26746912-3FF097CE-08ED-49FA-9013-318F3B9ECF2AQ30380599-1D16F468-892B-4A08-B1C8-162648F4C097Q31037436-31B638EF-0426-4FE2-BBD4-271EB1B4520EQ31162573-CB85C4CA-9EC7-4E20-99E6-2CE4461F5869Q33766568-7EEE8D20-7E7C-435F-889A-BD99154BC137Q34871881-E31EC898-F765-492C-88AD-ACBD1CF1CC47Q35284235-7575037D-1394-4803-8A1E-5334297400FAQ36614773-1858307C-1310-482E-8B23-03079F229C58Q38262775-FBF66DC9-27C4-4CE8-8DFA-11414D4462BEQ38573658-72A1BCC8-8325-4E4F-A596-C8C2DCC2DAB6Q38629975-033900CE-3D8F-4B16-8B53-7542D4BBCD96Q38661401-78837497-76FB-4384-9D5E-24AB05F853A6Q38831205-1707CDC5-E682-4521-9ADD-E9009FEDB3C9Q38868069-C4AA438D-BE4A-4606-A57C-CE9D9B0D6922Q38928616-E08B2ADD-7E92-498F-9AA8-C122065ED7E9Q38958062-9BC7095E-33BB-48D6-8AC4-C4110ED0D512Q40824411-57A4B06C-ED79-4B31-A54B-5D257039B8DBQ41922089-EDD387C8-F88D-477B-8692-B8118F0644C2Q41987423-99E71DAF-561A-4479-BD26-B20240AC56C1Q42029428-85D51DE4-FEC1-4F0F-A844-6CF70B8FAF6AQ47221355-CFFA2685-FE77-4895-AD4C-021C25037872Q47433211-AD979D1C-0DE2-472B-B94B-271FCBF5E933Q47623979-519212F2-AF93-4157-8311-18FBDA8B1DC9Q48185022-77E3DD02-8AD0-47A4-B55B-FFD72F7D1FDAQ51020710-9317555C-F094-48F4-89E7-4D2E5D471A03Q51292106-A9AE30A7-48EC-49ED-9D4D-7DB6816873B9Q51324124-54AEFE27-F466-4086-9A0A-39F43FF3FB57Q52818479-CAE28741-7674-4964-9CB2-7C38B30D41D8Q52921529-E06648B7-9045-4158-B099-E7ADA879D6F4Q53115625-0440B92F-A79B-4807-9634-4DBC6A671E62Q55510209-2239A7DC-AE85-447D-9462-66D6E0920962Q58578289-6C712B1F-28B7-402C-8FEA-ED52EEACCFDAQ58726467-52118D41-706E-4B88-AD51-C03F20CF8755Q59113090-6824EF48-827F-4E60-A5FD-D1855F55387A
P2860
Drug nanocrystals in the commercial pharmaceutical development process.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Drug nanocrystals in the commercial pharmaceutical development process.
@en
type
label
Drug nanocrystals in the commercial pharmaceutical development process.
@en
prefLabel
Drug nanocrystals in the commercial pharmaceutical development process.
@en
P1476
Drug nanocrystals in the commercial pharmaceutical development process.
@en
P2093
Jan P Möschwitzer
P304
P356
10.1016/J.IJPHARM.2012.09.034
P407
P577
2012-09-21T00:00:00Z